559 related articles for article (PubMed ID: 28664931)
1. The evolution of brachytherapy for prostate cancer.
Zaorsky NG; Davis BJ; Nguyen PL; Showalter TN; Hoskin PJ; Yoshioka Y; Morton GC; Horwitz EM
Nat Rev Urol; 2017 Jun; 14(7):415-439. PubMed ID: 28664931
[TBL] [Abstract][Full Text] [Related]
2. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S
Sci Rep; 2021 Mar; 11(1):6165. PubMed ID: 33731856
[TBL] [Abstract][Full Text] [Related]
4. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
[TBL] [Abstract][Full Text] [Related]
6. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
[TBL] [Abstract][Full Text] [Related]
7. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
[TBL] [Abstract][Full Text] [Related]
8. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
9. High dose rate brachytherapy boost for prostate cancer: a systematic review.
Zaorsky NG; Doyle LA; Yamoah K; Andrel JA; Trabulsi EJ; Hurwitz MD; Dicker AP; Den RB
Cancer Treat Rev; 2014 Apr; 40(3):414-25. PubMed ID: 24231548
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men.
Li Y; Chan Kong Ngai T; Zhou S; Yap Haw Hwong J; Pang Pei Ping E; Ong Li Kuan A; Wang Lian Chek M; Chua Lee Kiang M; Looi WS; Nei WL; Chua ET; On WLK; Tan Wee Kiat T; Yuen Shyi Peng J; Tuan Kit Loong J
Acta Oncol; 2021 Oct; 60(10):1291-1295. PubMed ID: 34259123
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
12. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
13. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
14. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
15. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
17. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer.
Ong WL; Evans M; Papa N; Williams S; Millar J
J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817
[TBL] [Abstract][Full Text] [Related]
18. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
19. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
